Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Erythropoietin Clear all
Completed Phase 2 Interventional Results available

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

NCT01244763
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
35
States / cities
Mobile, Alabama • Pine Bluff, Arkansas • Azusa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 1 Interventional

A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

NCT01170078
View directory record Official record
Conditions
Chronic Renal Failure
Interventions
Epoetin Hospira, Epogen
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Downey, California • Tarzana, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects

NCT00368238
View directory record Official record
Conditions
Healthy Subjects
Interventions
Recombinant human erythropoietin alfa (drug), Aspirin (drug), Clopidogrel (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 40 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2006 · Synced Oct 19, 2026, 10:19 AM EDT
Terminated Phase 2 Interventional Results available

Mechanisms of EPO-induced Hypertension

NCT03810911
View directory record Official record
Conditions
Chronic Kidney Disease, Blood Pressure, Anemia
Interventions
Darbepoetin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 19, 2026, 10:19 AM EDT
Terminated Phase 2 Interventional Results available

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

NCT00210626
View directory record Official record
Conditions
Anemia
Interventions
PROCRIT, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Santa Barbara, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597584
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin alfa or Epoetin beta
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • McGehee, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Not applicable Interventional

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia

NCT00002042
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 4 Interventional

A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

NCT00153868
View directory record Official record
Conditions
Anemia, Cancer
Interventions
darbepoetin alfa
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions
Erythropoietin, Sham Comparator
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Days
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
9
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2 Interventional

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

NCT00004914
View directory record Official record
Conditions
Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa, physical therapy
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2 Interventional

Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00072059
View directory record Official record
Conditions
Anemia, Lung Cancer
Interventions
methoxy polyethylene glycol epoetin beta
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2 Interventional

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

NCT01975818
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY 85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Azusa, California • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

NCT00048035
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2 Interventional

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00077311
View directory record Official record
Conditions
Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
Interventions
darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
64
States / cities
Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 4 Interventional

Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

NCT00224068
View directory record Official record
Conditions
Anemia
Interventions
Sodium ferric gluconate, ferrous sulfate, standard of care
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
32
States / cities
Bakersfield, California • Chula Vista, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2012 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

NCT04410198
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease (ESRD)
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Englewood, Colorado • Caldwell, Idaho • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

NCT00378352
View directory record Official record
Conditions
Acute ST Elevation Myocardial Infarction
Interventions
Epoetin alfa
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
16
States / cities
Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 19, 2026, 10:19 AM EDT
Terminated Phase 2 Interventional Results available

Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

NCT00398047
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
Azacitadine and Hematopoietic Growth Factors
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02892149
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
127
States / cities
Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 3 Interventional

Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia

NCT00017004
View directory record Official record
Conditions
Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Drug Toxicity, Radiation Toxicity, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions
External Beam Radiation Therapy, Cisplatin, Internal Radiation Therapy, Epoetin Alfa
Radiation · Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy

NCT00737893
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
Placebo, Erythropoietin (EPO)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Not applicable Interventional

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

NCT00002071
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 2 Interventional

The Effect of Human Recombinant Erythropoietin in Acute Renal Failure

NCT03102021
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
erythropoietin, saline
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 19, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

High-dose Erythropoietin for Asphyxia and Encephalopathy

NCT02811263
View directory record Official record
Conditions
Neonatal Encephalopathy, Birth Asphyxia
Interventions
Normal saline placebo, Erythropoietin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 24 Hours
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 19, 2026, 10:19 AM EDT